newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No